Market Cap | 16.16M | P/E | - | EPS this Y | 24.70% | Ern Qtrly Grth | - |
Income | -17.78M | Forward P/E | -0.65 | EPS next Y | -10.50% | 50D Avg Chg | -20.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -51.00% |
Dividend | N/A | Price/Book | 0.26 | EPS next 5Y | - | 52W High Chg | -78.00% |
Recommedations | 2.00 | Quick Ratio | 3.96 | Shares Outstanding | 15.84M | 52W Low Chg | 27.00% |
Insider Own | 1.98% | ROA | -13.92% | Shares Float | 15.53M | Beta | 1.39 |
Inst Own | 8.08% | ROE | -26.26% | Shares Shorted/Prior | 430.93K/540.04K | Price | 1.02 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 166,973 | Target Price | 5.50 |
Oper. Margin | - | Earnings Date | Mar 14 | Volume | 57,789 | Change | 0.99% |
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.